Search Results

Filter
  • 1-10 of  26,258 results for ""CLOZAPINE""
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

Clozapine-N-oxide protects dopaminergic neurons against rotenone-induced neurotoxicity by preventing ferritinophagy-mediated ferroptosis.

  • Authors : Sun Q; National-Local Joint Engineering Research Center for Drug-Research and Development (R & D) of Neurodegenerative Diseases, Dalian Medical University, No. 9 W. Lvshun South Road, Dalian 116044, China; Department of Neurology, Dalian University Affiliated Xinhua Hospital, No. 156 W. Wansui Road, Dalian 116021, China.

Subjects: Clozapine*/Clozapine*/Clozapine*/pharmacology ; Clozapine*/Clozapine*/Clozapine*/metabolism ; Neuroprotective Agents*/Neuroprotective Agents*/Neuroprotective Agents*/pharmacology

  • Source: Free radical biology & medicine [Free Radic Biol Med] 2024 Feb 20; Vol. 212, pp. 384-402. Date of Electronic Publication: 2024 Jan 03.Publisher: Elsevier Science Country of Publication: United States NLM ID: 8709159 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

The cardiovascular toxicity of clozapine in embryonic zebrafish and RNA sequencing-based transcriptome analysis.

  • Authors : Ding Z; Department of Pathology, School of Basic Medicine, Anhui Medical University, Hefei, 230032, China.; Department of Forensic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.

Subjects: Zebrafish* ; Clozapine*/Clozapine*/Clozapine*/toxicity ; Clozapine*/Clozapine*/Clozapine*/metabolism

  • Source: Journal of applied toxicology : JAT [J Appl Toxicol] 2024 Feb; Vol. 44 (2), pp. 175-183. Date of Electronic Publication: 2023 Aug 22.Publisher: John Wiley And Sons Country of Publication: England NLM ID: 8109495 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

CYP-catalysed cycling of clozapine and clozapine- N -oxide promotes the generation of reactive oxygen species in vitro .

  • Authors : Kingston E; Department of Pharmacology and Clinical Pharmacology, The University of Auckland, Auckland, New Zealand.; Tingle M

Subjects: Clozapine* ; Antipsychotic Agents*/Antipsychotic Agents*/Antipsychotic Agents*/toxicity ; Antipsychotic Agents*/Antipsychotic Agents*/Antipsychotic Agents*/metabolism

  • Source: Xenobiotica; the fate of foreign compounds in biological systems [Xenobiotica] 2024 Jan; Vol. 54 (1), pp. 26-37. Date of Electronic Publication: 2023 Dec 22.Publisher: Informa Healthcare Country of Publication: England NLM ID: 1306665 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Proof-of-concept evidence for high-density EEG investigation of sleep slow wave traveling in First-Episode Psychosis.

  • Authors : Castelnovo A; Sleep Medicine Unit, Neurocenter of Italian Switzerland, Ente Ospedaliero Cantonale (EOC), Via Tesserete 46, 6900, Lugano, Switzerland. .; Faculty of Biomedical Sciences, University of Italian Switzerland, Lugano, Switzerland. .

Subjects: Clozapine* ; Psychotic Disorders* ; Schizophrenia*/Schizophrenia*/Schizophrenia*/drug therapy

  • Source: Scientific reports [Sci Rep] 2024 Mar 21; Vol. 14 (1), pp. 6826. Date of Electronic Publication: 2024 Mar 21.Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

NMDA glutamate receptor antagonist MK-801 induces proteome changes in adult human brain slices which are partially counteracted by haloperidol and clozapine.

  • Authors : de Almeida V; Laboratory of Neuroproteomics, Department of Biochemistry and Tissue Biology, Institute of Biology, University of Campinas (UNICAMP), Campinas, Brazil.; Mendes ND

Subjects: Clozapine*/Clozapine*/Clozapine*/pharmacology ; Antipsychotic Agents*/Antipsychotic Agents*/Antipsychotic Agents*/pharmacology; Animals

  • Source: Journal of neurochemistry [J Neurochem] 2024 Mar; Vol. 168 (3), pp. 238-250. Date of Electronic Publication: 2024 Feb 08.Publisher: Wiley on behalf of the International Society for Neurochemistry Country of Publication: England NLM ID: 2985190R Publication Model: Print-Electronic

Record details

×
Academic Journal

Rare variants in pharmacogenes influence clozapine metabolism in individuals with schizophrenia.

  • Authors : Kappel DB; Centre for Neuropsychiatric Genetics and Genomics, Division of Psychological Medicine and Clinical Neurosciences, School of Medicine, Cardiff University, Cardiff, United Kingdom.; Rees E

Subjects: Clozapine*/Clozapine*/Clozapine*/adverse effects ; Schizophrenia*/Schizophrenia*/Schizophrenia*/drug therapy ; Schizophrenia*/Schizophrenia*/Schizophrenia*/genetics

  • Source: European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology [Eur Neuropsychopharmacol] 2024 Mar; Vol. 80, pp. 47-54. Date of Electronic Publisher: Elsevier Country of Publication: Netherlands NLM ID: 9111390 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Higher orexin-A levels are associated with treatment response to clozapine in patients with schizophrenia: A cross-sectional study.

  • Authors : Chen PY; Department of Psychiatry, Taipei City Psychiatric Center, Taipei City Hospital, Taipei, Taiwan.; Department of Psychiatry, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.

Subjects: Clozapine*/Clozapine*/Clozapine*/therapeutic use ; Schizophrenia*/Schizophrenia*/Schizophrenia*/complications ; Antipsychotic Agents*/Antipsychotic Agents*/Antipsychotic Agents*/therapeutic use

  • Source: Journal of psychopharmacology (Oxford, England) [J Psychopharmacol] 2024 Mar; Vol. 38 (3), pp. 258-267. Date of Electronic Publication: 2024 Jan 27.Publisher: Sage Publications Country of Publication: United States NLM ID: 8907828 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Virtual twins for model-informed precision dosing of clozapine in patients with treatment-resistant schizophrenia.

  • Authors : Mostafa S; Centre for Medicine Use and Safety, Monash University, Parkville, Victoria, Australia.; MyDNA Life Australia Limited, Victoria, Australia.

Subjects: Clozapine*/Clozapine*/Clozapine*/pharmacokinetics ; Clozapine*/Clozapine*/Clozapine*/therapeutic use ; Antipsychotic Agents*/Antipsychotic Agents*/Antipsychotic Agents*/pharmacokinetics

  • Source: CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2024 Mar; Vol. 13 (3), pp. 424-436. Date of Electronic Publication: 2024 Jan 19.Publisher: Wiley Country of Publication: United States NLM ID: 101580011 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

×
Academic Journal

Involvement of Extracellular Vesicles in the Proinflammatory Response to Clozapine: Implications for Clozapine-Induced Agranulocytosis.

  • Authors : Sernoskie SC; Departments of Pharmaceutical Sciences, Faculty of Pharmacy (S.C.S., J.U.) and Pharmacology and Toxicology, Temerty Faculty of Medicine (A.J., J.U.), University of Toronto, Toronto, Ontario; and Institute for Research in Immunology and Cancer (É.B., P.T.) and Department of Chemistry (P.T.), University of Montreal, Montreal, Quebec.

Subjects: Clozapine*/Clozapine*/Clozapine*/adverse effects ; Clozapine*/Clozapine*/Clozapine*/metabolism ; Agranulocytosis*/Agranulocytosis*/Agranulocytosis*/chemically induced

  • Source: The Journal of pharmacology and experimental therapeutics [J Pharmacol Exp Ther] 2024 Feb 15; Vol. 388 (3), pp. 827-845. Date of Electronic Publication: 2024 Feb 15.Publisher: American Society for Pharmacology and Experimental Therapeutics Country of Publication: United States NLM ID: 0376362 Publication Model: Electronic

Record details

×
Academic Journal

CLEAR - clozapine in early psychosis: study protocol for a multi-centre, randomised controlled trial of clozapine vs other antipsychotics for young people with treatment resistant schizophrenia in real world settings.

  • Authors : Casetta C; Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK. .; South London and Maudsley NHS Foundation Trust, London, UK. .

Subjects: Antipsychotic Agents*/Antipsychotic Agents*/Antipsychotic Agents*/adverse effects ; Clozapine*/Clozapine*/Clozapine*/adverse effects ; Schizophrenia*/Schizophrenia*/Schizophrenia*/therapy

  • Source: BMC psychiatry [BMC Psychiatry] 2024 Feb 14; Vol. 24 (1), pp. 122. Date of Electronic Publication: 2024 Feb 14.Publisher: BioMed Central Country of Publication: England NLM ID: 100968559 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-244X

Record details

×
  • 1-10 of  26,258 results for ""CLOZAPINE""